Exp Clin Endocrinol Diabetes 2011; 119(1): 59-61
DOI: 10.1055/s-0030-1262874
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Relationship Between HbA1c on Target, Risk of Silent Hypoglycemia and Glycemic Variability in Patients with Type 2 Diabetes Mellitus

B. Engler1 , C. Koehler1 , C. Hoffmann1 , W. Landgraf2 , 3 , S. Bilz1 , C. Schoner1 , S. R. Bornstein3 , M. Hanefeld1
  • 1GWT-TUD GmbH, Center for Clinical Studies, Dresden, Germany
  • 2Sanofi-Aventis, Berlin, Germany
  • 3Technical University of Dresden, Department of Medicine, Dresden, Germany
Further Information

Publication History

received 26.04.2010 first decision 13.07.2010

accepted 21.07.2010

Publication Date:
18 January 2011 (online)

Abstract

Objective: We aimed to compare time spent at low glucose level (silent hypoglycemia, glucose <3.0 mmol/l) and glycemic variability in patients who reached HbA1c <7.0% with those who did not.

Research Design and Methods: In 108 type 2 diabetic patients the interstitial glucose concentration was measured with CGMS (Continuous Glucose Monitoring System) over 72 h. Patients were divided in group 1 with an HbA1c <7.0% (n=63) and group 2 with an HbA1c≥7.0% (n=45).

Results: 24% in group 1 experienced silent hypoglycemia vs. 11% in group 2 (n. s.), duration of silent hypoglycemia over 48 h was 27±71 min vs. 7±36 min (n. s.). This was also valid for the subgroups treated with insulin. Patients in group 2 had a significantly higher standard deviation of average glucose (2.3±0.8 vs. 1.3±0.6; p<0.001) and MAGE (mean amplitude of glycemic excursions) (4.8±2.1 vs. 2.6±1.1; p<0.001).

Conclusion: Silent hypoglycemia tended to occur more often and to last longer in patients with HbA1c <7%. However, patients with HbA1c >7% had a higher glycemic variability. HbA1c >7% wasn’t a reliable indicator of lower risk of hypoglycemia.

References

  • 1 Action to Control Cardiovascular Risk in Diabetes Study Group. . Gerstein HC,, Miller ME, Byington RP. et al . Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 (24) 2545-2559
  • 2 American Diabetes Association. . Standards of Medical Care in Diabetes – 2009.  Diabetes Care. 2009;  32 (Suppl. 1) 13-61
  • 3 Desouza C, Salazar H, Cheong B. et al . Association of hypoglycemia and cardiac ischemia.  Diabetes Care. 2003;  26 1485-1489
  • 4 Gill GV, Woodward A, Casson IF. et al . Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes – the ‘dead in bed’ syndrome revisited.  Diabetologia. 2009;  52 42-45
  • 5 Hanefeld M, Koehler C, Hoffmann C. et al . Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes.  Diabetic medicine. 2010;  27 175-180
  • 6 Hirsch IB. Glycemic Variability: It's not just about A1c anymore.  Diabetes Technology & Therapeutics. 2005;  7 780-783
  • 7 Holman RR, Farmer AJ, Davies MJ. et al . 4-T Study Group: Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes.  N Engl J Med. 2009;  361 1736-1747
  • 8 Monnier L, Mas E, Ginet C. et al . Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.  JAMA. 2006;  295 1681-1687
  • 9 Kosiborod M, Inzucchi SE, Goyal A. et al . Relationship between spontaneous and iatrogenic hypoglycaemia in patients hospitalized with acute myocardial infarction.  JAMA. 2009-07-10;  301 1556-1564
  • 10 Service FJ, Molnar GD, Rosevear JW. et al . Mean amplitudes of glycemic excursions, a measure of diabetes instability.  Diabetes. 1970;  19 (9) 644-655

Correspondence

M. Hanefeld

GWT-TUD GmbH

Center for clinical studies

Fiedlerstraße 34

01307 Dresden

Germany

Phone: + 49/351/4400 580

Fax: + 49/351/4400 581

Email: hanefeld@gwtonline-zks.de

    >